Bristol, United Kingdom

Belinda Mary Kumpel


Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Location History:

  • Congresbury, GB (1996)
  • Bristol, GB (1996 - 1997)

Company Filing History:


Years Active: 1996-1997

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Belinda Mary Kumpel: Innovator in Monoclonal Antibodies

Introduction

Belinda Mary Kumpel is a distinguished inventor based in Bristol, GB. She has made significant contributions to the field of immunology, particularly in the development of human monoclonal antibodies. With a total of 4 patents to her name, her work has had a profound impact on medical science.

Latest Patents

Kumpel's latest patents include groundbreaking inventions related to human anti-Rh(D) monoclonal antibodies. The first patent describes human monoclonal antibodies that bind to the Rh(D) antigen while not interacting with other antigens of the Rh blood group system. These antibodies are characterized as IgG1 proteins with kappa light chains and are designed for Rh-typing of red blood cells and passive immunization to prevent hemolytic disease of the newborn. The second patent similarly outlines human monoclonal antibodies that are IgG3 proteins and bind to the same antigens, further emphasizing their utility in medical applications.

Career Highlights

Belinda Kumpel is currently associated with the National Blood Authority, where she continues her research and development efforts. Her work has been pivotal in advancing the understanding and application of monoclonal antibodies in clinical settings.

Collaborations

Kumpel has collaborated with notable colleagues, including Alan Doyle and Benjamin Arthur De Burgh Bradley, contributing to a rich environment of innovation and research.

Conclusion

Belinda Mary Kumpel's contributions to the field of immunology through her patents on monoclonal antibodies highlight her role as a leading inventor. Her work not only advances scientific knowledge but also has practical implications for healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…